Halozyme Therapeutics, Inc. (NASDAQ:HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced the appointment of Jeffrey W. Hendersonto its board of directors. Henderson brings nearly 30 years of financial, commercial and pharmaceutical industry expertise to the board, most recently serving for almost 10 years as chief financial officer of $100-billion health care products and services company, Cardinal Health.

“We are delighted to appoint an industry executive of Jeff’s caliber to the Halozyme board,” said Dr. Helen Torley, president and chief executive officer. “Jeff brings great depth from his business experience in strategy, finance, M&A and commercial operations that will complement our board’s expertise as we grow the company and prepare for the potential commercialization of our investigational new oncology drug, PEGPH20.”

Henderson served as CFO of Cardinal Health from 2005 until late last year, playing a key role in the company’s growth and transformation. During his tenure, the company acquired more than 30 companies, spun-off or sold multi-billion-dollar businesses and expanded into new geographies and market segments. In addition to his financial responsibilities, Henderson also managed commercial operations inChina and Canada.

Prior to Cardinal Health, Henderson was president and general manager of Eli Lilly Canada Inc. and vice president and corporate controller of Eli Lilly & Co. He joined Lilly in 1998 as vice president and corporate treasurer. His prior experience included 10 years at General Motors Corp., where he served executive and managerial posts in Great Britain, Singapore, New York and Canada. He received his Bachelor of Science degree in electrical engineering from Kettering University, Flint, Mich., and his Master of Business Administration degree from Harvard Graduate School of Business Administration. Henderson is a native of St. Catharines, Ontario, Canada. (Original Source)

Shares of Halozyme Therapeutics closed today at $23.42, up $0.11 or 0.47% . HALO has a 1-year high of $25.25 and a 1-year low of $7.51. The stock’s 50-day moving average is $22.67 and its 200-day moving average is $17.53.

On the ratings front, Halozyme has been the subject of a number of recent research reports. In a report issued on July 9, UBS analyst Andrew Peters reiterated a Buy rating on HALO, with a price target of $28, which represents a potential upside of 19.6% from where the stock is currently trading. Separately, on June 4, JMP’s Jason Butler maintained a Buy rating on the stock and has a price target of $21.

According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Andrew Peters and Jason Butler have a total average return of 15.6% and 67.5% respectively. Peters has a success rate of 61.1% and is ranked #910 out of 3724 analysts, while Butler has a success rate of 75.0% and is ranked #65.

Halozyme Therapeutics Inc is a biopharmaceutical company. It is engaged in research on human enzymes that alter the extracellular matrix and tumor environment.